Lanrod (Lanreotide)

Lanreotide binds to somatostatin receptors SSTR2 and SSTR5 on endocrine and neuroendocrine cells. This binding blocks adenylate cyclase, reduces cyclic AMP, and suppresses the secretion of growth hormone, insulin, glucagon, and other peptide hormones, thereby moderating the hormonal excess that drives the targeted diseases.

The specific dose and dosing interval of Lanrod are determined by the prescribing clinician based on the individual patient's condition, disease severity, and response to therapy. Dosage adjustments are made according to clinical guidelines and patient monitoring.

Safety data for lanreotide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Lanrod, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and necessary import documentation.

Lanrod (lanreotide) and other analogs such as octreotide share a similar mechanism of receptor binding but differ in formulation, dosing frequency, and pharmacokinetic profile. Lanreotide is often administered as a long‑acting injectable, allowing less frequent dosing compared with some short‑acting alternatives.

Lanrod should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

Lanrod is given by subcutaneous injection, typically into the abdominal wall or thigh. The injection is performed by a healthcare professional or a trained patient following aseptic technique and the specific administration instructions provided by the prescriber.

Serious risks include gallstone formation, acute pancreatitis, severe hypersensitivity reactions such as anaphylaxis, and marked hyperglycemia that may require medical intervention. Patients should be monitored closely for these events, especially during the initial treatment period.

Lanrod is contraindicated in individuals with known hypersensitivity to lanreotide or any of the formulation excipients. Caution is also advised for patients with severe uncontrolled diabetes, active gallbladder disease, or those who are pregnant or breastfeeding unless clearly indicated by a physician.